about
Adipocytokines: mediators linking adipose tissue, inflammation and immunityEvolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesisMicrobiota and diabetes: an evolving relationship.Adiponectin and its receptors in patients with chronic hepatitis C.Erythropoietin contrastingly affects bacterial infection and experimental colitis by inhibiting nuclear factor-κB-inducible immune pathwaysMalnutrition and microbiota--a new relationship?Non-alcoholic steatohepatitis: a microbiota-driven disease.Adipose and liver expression of interleukin (IL)-1 family members in morbid obesity and effects of weight loss[Recommendations for the use of faecal microbiota transplantation "stool transplantation": consensus of the Austrian Society of Gastroenterology and Hepatology (ÖGGH) in cooperation with the Austrian Society of Infectious Diseases and Tropical MedicFood, immunity, and the microbiome.Adiponectin and its receptors in non-alcoholic steatohepatitis.The RANKL/OPG system is activated in inflammatory bowel disease and relates to the state of bone lossSelective Targeting of a Disease-Related Conformational Isoform of Macrophage Migration Inhibitory Factor Ameliorates Inflammatory Conditions.Lipocalin 2 Protects from Inflammation and Tumorigenesis Associated with Gut Microbiota Alterations.Dietary Factors: Major Regulators of the Gut's Microbiota.Lipocalin-2 ensures host defense against Salmonella Typhimurium by controlling macrophage iron homeostasis and immune responseMode of function of biological anti-TNF agents in the treatment of inflammatory bowel diseases.Role of adiponectin and PBEF/visfatin as regulators of inflammation: involvement in obesity-associated diseases.Suppression of interleukin-17 by type I interferons: a contributing factor in virus-induced immunosuppression?Obesity and the microbiota.Pre-B cell colony enhancing factor/NAMPT/visfatin in inflammation and obesity-related disorders.Update on nonalcoholic fatty liver disease: genes involved in nonalcoholic fatty liver disease and associated inflammation.Weight loss: cornerstone in the treatment of non-alcoholic fatty liver disease.Adiponectin: key player in the adipose tissue-liver crosstalk.Inflammation, cytokines and insulin resistance: a clinical perspective.Liver complications in inflammatory bowel diseases.Metabolic inflammation: role of cytokines in the crosstalk between adipose tissue and liver.Targeting T and B lymphocytes in inflammatory bowel diseases: lessons from clinical trials.Evolving therapies for non-alcoholic steatohepatitis.Mechanisms behind the link between obesity and gastrointestinal cancers.Interleukin-1 and inflammasomes in alcoholic liver disease/acute alcoholic hepatitis and nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.Blockade of receptor activator of nuclear factor-κB (RANKL) signaling improves hepatic insulin resistance and prevents development of diabetes mellitus.Interleukin-32: a new proinflammatory cytokine involved in hepatitis C virus-related liver inflammation and fibrosis.Lipocalin 2 drives neutrophilic inflammation in alcoholic liver disease.Fibrates ameliorate the course of bacterial sepsis by promoting neutrophil recruitment via CXCR2.Proinflammatory wheat attacks on the intestine: alpha-amylase trypsin inhibitors as new players.Overexpression of indoleamine 2,3-dioxygenase in human inflammatory bowel disease.Interferon-alpha controls IL-17 expression in vitro and in vivo.A key role for Pre-B cell colony-enhancing factor in experimental hepatitis.Adipose tissue and liver expression of SIRT1, 3, and 6 increase after extensive weight loss in morbid obesity.
P50
Q29619393-4768EBDE-BFD5-403E-9F9F-39648D0A14DDQ29619888-54736A32-D9E8-4E4A-BA1D-A5A33CE58B64Q34420231-A542A26A-75C8-4FA2-A861-7052F90A6D57Q34448049-751AAD6F-1196-4CB0-A214-44DF2288DA1EQ34544348-67D5E761-E7BD-4DD3-8907-14454F9BE60EQ34626866-18343AF7-3F23-4E9B-A14F-70090A2412E0Q34798884-F54B38EF-56E7-488D-BE6E-E841264CC639Q35136724-3C0F95D5-7962-4E26-BC6F-E6747A38F63DQ35489037-79F1C708-CB33-49EF-8AC6-DB92E4DCF945Q35540916-9D3F2303-3827-47D9-992C-FC4F795E1B69Q35597147-24456994-B2D5-4AD4-AC3D-D2B8977BAA4AQ35597297-9B69A981-0468-45B9-BFD3-C0A0C40BA61EQ35979041-8BE21F90-C6D2-4001-AF29-A02A86EF05F6Q35989783-7B08036D-0E1D-47FC-8F0C-F049AD2C0A15Q36385143-77F6E028-FD9E-42AA-83BA-7DEACE3BD287Q36396704-00E3F53B-9D29-423D-BBD0-00D789B25310Q36897403-46B7CA3E-94DB-42F9-A787-9D7AF429A468Q37056669-C66F0617-0ED5-4629-957C-78CFAEA6F81CQ37422784-8BB663CC-BE5F-4FBF-9A9A-B69E794A92C7Q37425368-F042C359-4D68-474F-B47E-FB81AD8DD955Q37725006-38C5FFEA-CABC-45A9-9A65-BA01B78B8DD1Q37753812-614B1337-00CA-4AA0-B7DB-BBDAFDDA3323Q37756509-C03C2626-3447-424F-85C8-425341E39F22Q38033220-5AB3CD1F-EF1D-497C-8571-F7AA51CAABD4Q38073137-8127CEE9-7F5B-46C3-8B97-1002A623A1DFQ38136959-AC4A95D8-649B-4DA6-B44D-F636540CEE08Q38151767-C0610E50-A758-41A9-B829-FFE1A7136EDAQ38163737-B7D6AC8A-557F-4FA3-A062-D2D10BD96258Q38207111-A5458875-AFAD-46DF-8939-F5009459E430Q38246469-77EC259A-FF1F-4234-8F94-B0216EB79C46Q38698442-4E3B4DDB-8937-4245-A105-32D8728C0DBCQ39197051-283B44DE-9CE4-4342-8479-47191784E18FQ39580319-18499E9C-1899-48F5-970D-D0AF5D4FF358Q40865906-0ED23712-5A38-47EF-8473-BFB5939EF6E9Q42218338-8A2D3054-EA32-4B15-8D60-58D6CC4C5B53Q44804102-6A49BABE-E842-4A8D-9F47-0D5629E5990CQ45068428-1A1452A8-66C0-45CE-9707-A574504929B7Q45849810-739A12E8-815D-45C2-9DB5-DFE98541CFF3Q46776529-AC65B03E-780C-4C8D-8871-9C43638B8AB5Q46910461-B4AADBC6-96C1-472B-98BF-0E6E00676F9C
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
ricercatore
@it
հետազոտող
@hy
name
Alexander R Moschen
@ast
Alexander R Moschen
@en
Alexander R Moschen
@es
Alexander R Moschen
@nl
Alexander R Moschen
@sl
type
label
Alexander R Moschen
@ast
Alexander R Moschen
@en
Alexander R Moschen
@es
Alexander R Moschen
@nl
Alexander R Moschen
@sl
prefLabel
Alexander R Moschen
@ast
Alexander R Moschen
@en
Alexander R Moschen
@es
Alexander R Moschen
@nl
Alexander R Moschen
@sl
P214
P106
P21
P214
P31
P496
0000-0003-3598-7848
P735
P7859
viaf-315215925